Skip to main content

Derek Nunez

Adjunct Professor in the Department of Medicine
Medicine, Endocrinology, Metabolism, and Nutrition

Selected Publications


GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells.

Journal Article Sci Adv · March 2021 Glucose-dependent insulinotropic polypeptide (GIP) communicates nutrient intake from the gut to islets, enabling optimal levels of insulin secretion via the GIP receptor (GIPR) on β cells. The GIPR is also expressed in α cells, and GIP stimulates glucagon ... Full text Link to item Cite

Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials.

Journal Article Am J Physiol Gastrointest Liver Physiol · March 1, 2019 Liver enzyme concentrations are measured as safety end points in clinical trials to detect drug-related hepatotoxicity, but little is known about the epidemiology of these biomarkers in subjects without hepatic dysfunction who are enrolled in drug trials. ... Full text Open Access Link to item Cite

Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.

Journal Article Diabetes Obes Metab · July 2016 AIMS: To investigate the pharmacodynamics, pharmacokinetics and safety/tolerability of blocking reuptake of bile acids using the inhibitor GSK2330672 (GSK672) in patients with type 2 diabetes (T2D). METHODS: Subjects with T2D taking metformin were enrolled ... Full text Link to item Cite

Therapeutic potential of akeda‐‐protein‐receptor‐5 () agonists. ope or hype?

Journal Article Diabetes, Obesity and Metabolism · May 2016 The gastrointestinal tract regulates glucose and energy metabolism, and there is increasing recognition that bile acids function as key signalling molecules in these processes. For example, bile acid changes that occur after bariatric surgery have ... Full text Cite

GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects.

Journal Article Diabetes Obes Metab · October 2015 We investigated the effects of a long-duration glucagon-like peptide-1 (GLP-1) receptor agonist, GSK2374697, on postprandial endogenous total GLP-1 and peptide YY (PYY). Two cohorts of healthy subjects, one normal/overweight and one obese, were randomized ... Full text Link to item Cite

Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.

Journal Article PLoS One · 2014 UNLABELLED: GPR119 receptor agonists improve glucose metabolism and alter gut hormone profiles in animal models and healthy subjects. We therefore investigated the pharmacology of GSK1292263 (GSK263), a selective GPR119 agonist, in two randomized, placebo- ... Full text Link to item Cite

Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB‐756050, in Type 2 Diabetes

Journal Article Clinical Pharmacology in Drug Development · July 2013 AbstractTGR5 is a bile acid receptor and a potential target for the treatment of type 2 diabetes (T2D). We report here the safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 ag ... Full text Cite

Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes

Journal Article Diabetes Care · November 1, 2012 OBJECTIVERemogliflozin etabonate (RE), an inhibitor of the sodium-glucose transporter 2, improves glucose profiles in type 2 diabetes. This study assessed safety, tolerability ... Full text Cite

The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.

Journal Article Clin Pharmacol Ther · May 2010 Precompetitive collaboration is a growing driver for innovation and increased productivity in biomedical science and drug development. The Biomarkers Consortium, a public-private platform for precompetitive collaboration specific to biomarkers, demonstrate ... Full text Link to item Cite